Company news
Insulet Corporation (NASDAQ:PODD) news
Insulet Corporation news releases on 6ix. Latest, Oct 1, 2026: Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026
Press releases & updates
Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026
September 30, 2026
Insulet to Announce Third Quarter 2026 Financial Results on November 4, 2026
October 1, 2026
Insulet to Participate in Bernstein Insights: Healthcare Leaders and Disruptors – 3rd Annual Healthcare Forum
September 18, 2026
Insulet to Participate in Wells Fargo 21st Annual Healthcare Conference
August 26, 2026
Insulet Reports Second Quarter 2026 Results
August 5, 2026
Insulet Partners with Calm to Bring Mindfulness and Well-Being Tools to the Diabetes Community, Featuring a New Sleep Story Narrated by Lila Moss
July 14, 2026
Insulet Accelerates Global Growth with Launch of Omnipod(R) 5 and Omnipod Discover in Spain, Expanding Access to Tubeless Diabetes Technology
July 7, 2026
Insulet Accelerates Global Growth with Launch of Omnipod® 5 and Omnipod Discover™ in Spain, Expanding Access to Tubeless Diabetes Technology
July 6, 2026
Insulet to Announce Second Quarter 2026 Financial Results on August 5, 2026
July 1, 2026
Insulet Announces Appointment of Jonathan J. Mazelsky to its Board of Directors
June 25, 2026
Insulet Reveals New Data Supporting Breakthrough Omnipod® 6 and Fully Closed-Loop AID Systems Designed to Improve Outcomes, Reduce Effort, and Unlock Barriers to Care
June 6, 2026
Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific Sessions
June 4, 2026
Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott’s FreeStyle Libre 3 Plus Sensor
June 3, 2026
Insulet to Participate in William Blair 46th Annual Growth Stock Conference
May 27, 2026
Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® Pods in the U.S. and Affected International Markets
May 26, 2026
Insulet Reports First Quarter 2026 Results
May 6, 2026
Insulet Unveils 2025 Sustainability Report Highlighting Strong Momentum Across Key Priorities
May 5, 2026
Insulet Initiates EVOLVE Pivotal Study to Advance Fully Closed-Loop Automated Insulin Delivery System for Type 2 Diabetes
May 4, 2026
Insulet to Participate in BofA Securities 2026 Health Care Conference
April 28, 2026
Insulet to Announce First Quarter 2026 Financial Results on May 6, 2026
March 31, 2026
Insulet Appoints Mike Panos as Chief Commercial Officer
March 29, 2026
Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® 5 Pods in the U.S.
March 12, 2026
Insulet Presents Promising Study Results for Fully Closed-Loop Automated Insulin Delivery System for Adults with Type 2 Diabetes
March 10, 2026
Insulet to Present EVOLUTION 2 Results on Omnipod® Fully Closed-Loop System for Adults with Type 2 Diabetes at International Conference on Advanced Technologies & Treatments for Diabetes (ATTD)
March 9, 2026
Insulet Reports Fourth Quarter and Full Year 2025 Results
February 18, 2026
Insulin Pump Market Insights $2.1B Revenue from Insulet, 500,000+ U.S. Users and 47.8% Adoption in Canada Driven by Government Funding
February 6, 2026
Insulet Launches Omnipod® 5 and Omnipod Discover™ in the Middle East to Transform Diabetes Care
February 5, 2026
Insulet to Announce Fourth Quarter and Full Year 2025 Financial Results on February 18, 2026
January 9, 2026
Insulet to Announce Fourth Quarter and Full Year 2025 Financial Results on February 18, 2026
January 8, 2026
Insulet Redefines Diabetes at CES with "Liveable Technology" — A New Frontier in Human-Centered Connected Health
January 6, 2026
Insulet to Participate in 44th Annual J.P. Morgan Healthcare Conference
December 15, 2025
Insulet Expands Omnipod® U.S. Recycling Program, Diverting Millions of Pods from Landfills and Creating a More Sustainable Future
December 14, 2025
Insulet Announces FDA 510(k) Clearance of Omnipod® 5 Algorithm Enhancements that Redefine Insulin Delivery and Simplify the Pod Experience
December 3, 2025
Insulet Outlines Long-Term Strategy to Drive Growth and Value Creation at 2025 Investor Day
November 19, 2025
Insulet Reports Third Quarter 2025 Results
November 5, 2025
Insulet Champions Workplace Inclusion for People with Diabetes with New Data and Tools Released for Diabetes Awareness Month
October 29, 2025
Insulet Announces Appointment of Robert L. Huffines to its Board of Directors
October 22, 2025
Insulet to Host Investor Day on November 20, 2025
October 9, 2025
Insulet and Pantone® Partner to Launch Omnipod® Mango in Vibrant New Palette
September 17, 2025
Insulet Announces CFO Transition
September 15, 2025
Insulet Elevates Eric Benjamin to Chief Operating Officer
August 24, 2025
Insulet to Participate in Upcoming Investor Conferences
August 18, 2025
Insulet Reports Second Quarter 2025 Revenue Increase of 32.9% Year-Over-Year (31.3% Constant Currency1)
August 7, 2025
Insulet Reports Second Quarter 2025 Revenue Increase of 32.9% Year-Over-Year (31.3% Constant Currency¹)
August 6, 2025
Insulet to Announce Second Quarter 2025 Financial Results on August 7, 2025
July 7, 2025
Insulet to Share Additional Evidence Demonstrating the Impact of Omnipod® 5 on Improved Health Outcomes at the American Diabetes Association 85th Scientific Sessions
June 18, 2025
Insulet’s Omnipod® 5 App for iPhone with Dexcom G7 Integration Now Available to all U.S. Users
June 9, 2025
Insulet to Present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025
May 22, 2025
Insulet Announces Publication of 2024 Sustainability Report
May 12, 2025
Insulet Reports First Quarter 2025 Revenue Increase of 29% Year-Over-Year (30% Constant Currency1)
May 8, 2025